SK282673B6 - Použitie (+) norcisapridu, farmaceutický prostriedok s obsahom (+) norcisapridu a jeho farmaceutická jednotková dávková forma - Google Patents

Použitie (+) norcisapridu, farmaceutický prostriedok s obsahom (+) norcisapridu a jeho farmaceutická jednotková dávková forma Download PDF

Info

Publication number
SK282673B6
SK282673B6 SK1239-98A SK123998A SK282673B6 SK 282673 B6 SK282673 B6 SK 282673B6 SK 123998 A SK123998 A SK 123998A SK 282673 B6 SK282673 B6 SK 282673B6
Authority
SK
Slovakia
Prior art keywords
norcisapride
pharmaceutically acceptable
disorder
acceptable salt
pharmaceutical
Prior art date
Application number
SK1239-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK123998A3 (en
Inventor
John R. Mccullough
Thomas P. Jerussi
Original Assignee
Sepracor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor, Inc. filed Critical Sepracor, Inc.
Publication of SK123998A3 publication Critical patent/SK123998A3/sk
Publication of SK282673B6 publication Critical patent/SK282673B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1239-98A 1996-07-19 1997-07-02 Použitie (+) norcisapridu, farmaceutický prostriedok s obsahom (+) norcisapridu a jeho farmaceutická jednotková dávková forma SK282673B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/684,753 US5739151A (en) 1996-07-19 1996-07-19 Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PCT/US1997/011629 WO1998003173A1 (en) 1996-07-19 1997-07-02 Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (2)

Publication Number Publication Date
SK123998A3 SK123998A3 (en) 1999-03-12
SK282673B6 true SK282673B6 (sk) 2002-11-06

Family

ID=24749413

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1239-98A SK282673B6 (sk) 1996-07-19 1997-07-02 Použitie (+) norcisapridu, farmaceutický prostriedok s obsahom (+) norcisapridu a jeho farmaceutická jednotková dávková forma

Country Status (25)

Country Link
US (3) US5739151A (pt)
EP (1) EP0896539B1 (pt)
JP (1) JP3097697B2 (pt)
KR (4) KR100533237B1 (pt)
CN (1) CN1215992A (pt)
AT (1) ATE197762T1 (pt)
AU (1) AU3592097A (pt)
BG (1) BG63190B1 (pt)
BR (1) BR9708287A (pt)
CA (1) CA2245768C (pt)
CZ (1) CZ293478B6 (pt)
DE (1) DE69703617T2 (pt)
DK (1) DK0896539T3 (pt)
ES (1) ES2152687T3 (pt)
GR (1) GR3035460T3 (pt)
HU (1) HUP9904360A3 (pt)
IL (1) IL125703A0 (pt)
IS (1) IS4820A (pt)
NO (2) NO317178B1 (pt)
NZ (1) NZ331291A (pt)
PL (1) PL189610B1 (pt)
PT (1) PT896539E (pt)
SK (1) SK282673B6 (pt)
TR (1) TR199801816T2 (pt)
WO (1) WO1998003173A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
DE69714279T2 (de) * 1996-10-15 2003-03-06 Janssen Pharmaceutica Nv Verfahren zur Herstellung eines Zwischenprodukts in der Cisapridsynthese
DK1000029T3 (da) * 1997-07-11 2004-02-23 Janssen Pharmaceutica Nv Norcisaprid nyttig med hensyn til 5-HT3- og 5-HT4- medierede lidelser
IL140118A0 (en) * 1998-06-15 2002-02-10 Sepracor Inc Use of optically pure (+) norcisapride for treating apnea, bulimia and other disorders
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
TR200103757T2 (tr) * 1998-06-15 2002-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
DK1104289T3 (da) * 1998-08-21 2006-05-15 Novartis Ag Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
PT1704146E (pt) 2004-01-07 2010-06-30 Aryx Therapeutics Inc Compostos estereoisoméricos e processos para o tratamento de distúrbios gastrointestinais e do sistema nervoso central
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
WO2006029520A1 (en) * 2004-09-14 2006-03-23 Mcgill University Stimulators of 5-ht4 receptors and uses thereof
AU2006284601B2 (en) * 2005-08-31 2012-12-20 Renexxion, Llc Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007149929A1 (en) * 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
BR112012008961A2 (pt) 2009-10-16 2019-09-24 Epiomed Therapeutics Inc tratamento de êmese
JP5980236B2 (ja) * 2011-02-25 2016-08-31 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ ジアミノピリミジン誘導体及びその製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114715A (en) * 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
US5114714A (en) * 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
CA2139636A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08512322A (ja) * 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
KR20000064524A (ko) 2000-11-06
BR9708287A (pt) 2000-01-18
KR100422492B1 (ko) 2004-03-11
ATE197762T1 (de) 2000-12-15
JP3097697B2 (ja) 2000-10-10
NZ331291A (en) 2000-06-23
BG102757A (en) 1999-08-31
KR100328731B1 (ko) 2002-10-19
CZ293478B6 (cs) 2004-05-12
AU3592097A (en) 1998-02-10
WO1998003173A1 (en) 1998-01-29
PT896539E (pt) 2001-05-31
CA2245768C (en) 2003-09-30
NO317178B1 (no) 2004-09-06
KR20040007505A (ko) 2004-01-24
HUP9904360A3 (en) 2001-07-30
NO983636D0 (no) 1998-08-07
DK0896539T3 (da) 2001-02-19
US6114356A (en) 2000-09-05
IS4820A (is) 1998-08-10
US5739151A (en) 1998-04-14
IL125703A0 (en) 1999-04-11
GR3035460T3 (en) 2001-05-31
CZ250898A3 (cs) 1999-04-14
KR100533237B1 (ko) 2005-12-05
HUP9904360A2 (hu) 2000-05-28
NO983636L (no) 1998-10-19
ES2152687T3 (es) 2001-02-01
KR100399808B1 (ko) 2003-09-29
TR199801816T2 (xx) 2000-10-23
CA2245768A1 (en) 1998-01-29
JPH11510828A (ja) 1999-09-21
CN1215992A (zh) 1999-05-05
EP0896539A1 (en) 1999-02-17
DE69703617D1 (de) 2001-01-04
PL335254A1 (en) 2000-04-10
SK123998A3 (en) 1999-03-12
PL189610B1 (pl) 2005-08-31
NO20041166L (no) 2004-03-19
US5877188A (en) 1999-03-02
BG63190B1 (bg) 2001-06-29
EP0896539B1 (en) 2000-11-29
DE69703617T2 (de) 2001-04-12

Similar Documents

Publication Publication Date Title
US5739151A (en) Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
EP0831821B1 (en) Optically pure (-) norcisapride for treating digestive tract disorders
US6147093A (en) Methods for treating gastroesophageal reflux disease
AU780107B2 (en) Methods for treating emesis and central nervous system disorders using optically pure () norcisapride
MXPA01000919A (en) Methods and compositions for treating gastro-esophageal reflux disease
AU2004200165A1 (en) Methods and compositions for treating gastro-esophageal reflux disease